Finally, as COVID-19 has a strong component of ACE2 depletion underlying the course of the illness, and as RAAS (angiotensin and aldosterone) stressors promote cytokine-mediated disease in the lungs ...

Second, there are conflicting data on the effects of RAAS inhibition on ACE2 expression and how it relates to clinical outcomes in COVID-19, including the potential for ACE inhibitors and ARBs to ...